Experimental Therapeutics Program (Project-003)

实验治疗学 摘要 亨斯迈癌症研究所（HCI）的实验治疗（ET）项目旨在促进 跨学科合作，加速以患者为导向的研究向临床转化的进程 和照顾癌症患者。该计划分为两个主要研究主题：药物 发现/药物递送和临床研究。计划成员致力于发现新的代理人， 开发用于靶向癌细胞的药物，开发第二代抗癌聚合物载体， 药物，设计大分子靶向治疗剂，对各种类型的 恶性肿瘤，并开发无药物的大分子治疗结构，以提高目前的疗效 使用的疗法。计划成员还确保在HCI执行临床研究和翻译 将癌症中心的重要发现应用于人类。计划成员还积极参与 领导和开展临床试验，包括制药商发起的试验。这一临床研究重点与 NCI的目标是开发和进行最先进的癌症治疗和先进的成像多， 机构临床试验，以评估新的癌症疗法和相关的临床方法，在广泛的 人群和癌症类型的范围。项目成员致力于改造以前的 NCI临床试验合作小组计划整合成一个统一的国家临床试验 网络（NCTN），通过提供临床试验领导和获得患者中至关重要的应计费用 在山间西部 该计划的目标是：1）提供个性化癌症治疗的新方法， 最先进的临床治疗，通过闪烁器启动的治疗，成像和成像引导 临床试验; 2）通过以下方式促进实验室和临床之间发现的双向转化： ET计划成员、其他计划成员和HCI之间的合作和科学协同作用 执业临床医生; 3）通过合作开发新疗法，以满足癌症未满足的临床需求 并与HCI多学科疾病组和疾病导向研究团队进行互动。 39名ET计划成员来自学校的11个不同的犹他州系 医学院、药学院和理学院。该计划包括24名教授，7名副教授， 教授，7名助理教授和1名讲师，11名博士，22名医学博士，6名医学博士，博士。资金 包括2013年总成本中的1480万美元（NCI：28%，其他NIH：20%，其他同行评审来源：15%）。从 2009-2013年，ET成员发表了550篇同行评审论文，其中28%涉及与其他组织的合作。 癌症中心成员和66%涉及外部合作伙伴关系。

EXPERIMENTAL THERAPEUTICS PROGRAM ABSTRACT The Experimental Therapeutics (ET) Program of Huntsman Cancer Institute (HCI) is organized to facilitate transdisciplinary collaboration and to accelerate the progress of patient-oriented research to clinical translation and care of patients with cancer. The Program is organized into two main research themes: Drug Discovery/Drug Delivery and Clinical Research. Program members work to discover new agents that can be developed into drugs used to target cancer cells, develop second-generation polymeric carriers of anticancer drugs, design macromolecular targeted therapeutics with selective inhibitory effects on various types of malignancy, and develop drug-free macromolecular therapeutic constructs to increase efficacy of currently used therapeutics. Program members also ensure the execution of clinical research at HCI and the translation of important Cancer Center discoveries to human applications. Program members are also active in the leadership and conduct of clinical trials, including investigator-initiated trials. This clinical research focus aligns with the goals of NCI to develop and conduct state-of-the-art cancer treatment and advanced imaging multi- institutional clinical trials to evaluate new cancer therapies and related clinical approaches across a broad range of populations and cancer types. Program members are engaged in the effort to transform the previous NCI Clinical Trials Cooperative Group Program into a consolidated and integrated National Clinical Trials Network (NCTN), by providing clinical trials leadership and access to vitally important accruals among patients in the Intermountain West. The goals of the program are to: 1) provide new approaches to individualized cancer treatment as well as the most up-to-date clinical treatments via investigator-initiated therapeutic, imaging, and imaging-guided clinical trials; 2) foster bidirectional translation of discoveries between the laboratory and the clinic through collaborations and scientific synergy among ET program members, other program members, and HCI practicing clinicians; 3) develop novel therapies to meet unmet clinical needs in cancer through collaboration and interaction with the HCI multidisciplinary disease groups and disease-oriented research teams. The 39 ET Program members are drawn from 11 different University of Utah departments in the School of Medicine and Colleges of Pharmacy and Science. The Program includes 24 professors, seven associate professors, seven assistant professors, and one instructor, with 11 PhDs, 22 MDs, and six MD, PhDs. Funding includes $14.8M in 2013 total costs (NCI: 28%, other NIH: 20%, other peer-reviewed sources: 15%). From 2009–2013, ET members published 550 peer-reviewed papers, of which 28% involved collaboration with other Cancer Center members and 66% involved external partnerships.